摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(5-氨基-2-羟基苯基)乙酰胺 | 23184-60-3

中文名称
N-(5-氨基-2-羟基苯基)乙酰胺
中文别名
——
英文名称
acetic acid-(5-amino-2-hydroxy-anilide)
英文别名
Essigsaeure-(5-amino-2-hydroxy-anilid);4-Amino-2-acetamino-phenol;2-acetylamino-4-aminophenol;N-(5-Amino-2-hydroxyphenyl)acetamide
N-(5-氨基-2-羟基苯基)乙酰胺化学式
CAS
23184-60-3
化学式
C8H10N2O2
mdl
MFCD12025926
分子量
166.18
InChiKey
MHEVFARIRDCFEO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    162°

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    75.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2924299090

SDS

SDS:aa07794bd0847def89d065396e642d61
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    N-(2-羟基-5-硝基苯基)乙酰胺 2-acetamido-4-nitrophenol 97-60-9 C8H8N2O4 196.163
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— N-(5-acetylamino-2-hydroxyphenyl)-acetamide 38847-62-0 C10H12N2O3 208.217
    —— (E)-N-(3-acetamido-4-hydroxyphenyl)-3-(3,4-dihydroxyphenyl)acrylamide 1440434-17-2 C17H16N2O5 328.324

反应信息

  • 作为反应物:
    参考文献:
    名称:
    CCCLVII.—氨基-1-甲基苯并恶唑及其向邻氨基苯酚的砷酸的转化
    摘要:
    DOI:
    10.1039/jr9300002685
  • 作为产物:
    描述:
    N-(2-羟基-5-硝基苯基)乙酰胺 在 palladium 10% on activated carbon 、 氢气 作用下, 以 甲醇 为溶剂, 生成 N-(5-氨基-2-羟基苯基)乙酰胺
    参考文献:
    名称:
    Caffeic acid derivatives: A new type of influenza neuraminidase inhibitors
    摘要:
    Recently, many natural products, especially some plant-derived polyphenols have been found to exert antiviral effects against influenza virus and show inhibitory activities on neuraminidases (NAs). In our research, we took caffeic acid which contained two phenolic hydroxyl groups as the basic fragment to build a small compound library with various structures. The enzyme inhibition result indicated that some compounds exhibited moderate activities against NA and compound 15d was the best with IC50 = 7.2 mu M and 8.5 mu M against N2 and N1 NAs, respectively. The 3,4-dihydroxyphenyl group from caffeic acid was important for the activity according to the docking analysis. Besides, compound 15d was found to be a non-competitive inhibitor with K-i = 11.5 +/- 0.25 mu M by the kinetic study and also presented anti-influenza virus activity in chicken embryo fibroblast cells. It seemed promising to discover more potent NA inhibitors from caffeic acid derivatives to cope with influenza virus. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.04.033
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2014060113A1
    公开(公告)日:2014-04-24
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种具有公式(I)的新化合物,能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
  • [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2014060112A1
    公开(公告)日:2014-04-24
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及具有式(I)的新化合物,其能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
  • NOVEL KINASE INHIBITORS
    申请人:ORIGENIS GMBH
    公开号:US20150259340A1
    公开(公告)日:2015-09-17
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及式(I)的新型化合物,能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体。这些化合物可用于治疗各种疾病。这些疾病包括自身免疫性疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
  • PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS
    申请人:ORIGENIS GMBH
    公开号:US20150266882A1
    公开(公告)日:2015-09-24
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及化合物(I)的新型化合物,能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体。这些化合物在治疗多种疾病方面有应用。这些疾病包括自身免疫疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼病、传染病和激素相关疾病。
  • Dye composition for keratinous fiber
    申请人:Kao Corporation
    公开号:EP0345728A2
    公开(公告)日:1989-12-13
    A hair dyeing composition comprising a special developer and a coupling agent is disclosed. The developer is a 4-aminophenol derivative substituted at the 2-position which is represented by the following formula (I), in which X represents a group -NHCOR¹ (R¹ is a linear or branched alkyl group having 1-5 carbon atoms), a group -COOR² [R² is a hydrogen atom, a linear or branched alkyl group having 1-5 carbon atoms, a monohydroxy alkyl group having 1-5 carbon atoms, a polyhydroxy alkyl group having 1-5 carbon atoms, or a group -(CH₂)nNR³R⁴ (R³ and R⁴ individually represent a hydrogen atom or a linear or branched alkyl group having 1-5 carbon atoms, and n denotes an integer of 1-5)], a group -CONHR², a nitrile group, a group -SO₃R², or a group -SO₂NR22 (R² has the same meaning as defined above and the two R²s may be the same or different), or a salt thereof. The dye composition provides a high degree of saturation and vividness of colors as well as good fastness.
    本发明公开了一种由特殊显影剂和偶联剂组成的染发组合物。该显影剂是一种在 2 位被取代的 4-氨基苯酚衍生物,由下式(I)表示、 其中 X 代表基团-NHCOR¹(R¹ 是具有 1-5 个碳原子的直链或支链烷基)、基团-COOR²[R² 是氢原子、具有 1-5 个碳原子的直链或支链烷基、具有 1-5 个碳原子的单羟基烷基、具有 1-5 个碳原子的多羟基烷基、或基团-(CH₂)nNR³R⁴(R³ 和 R⁴ 分别代表氢原子或具有 1-5 个碳原子的直链或支链烷基,n 表示 1-5 的整数)]、基团-CONHR²、腈基、基团-SO₃R² 或基团-SO₂NR22(R² 的含义与上述定义相同,两个 R² 可以相同或不同),或其盐。该染料组合物具有较高的色彩饱和度和鲜艳度以及良好的牢度。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐